Povidine-iodine
Phase 2Small molecule
Povidine-iodine is one of 10 small molecule programs targeting CLE. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in CLE
#DrugCompanyPhaseTrials
1Zytiga
Johnson & JohnsonPhase 3
Zuragard
ZZurex Pharma, Inc.
Phase 2
Keto Acid
UUniversity Hospital, Clermont-Ferrand
Phase 3
Brethine
SanofiPreclinical
Povidine-iodine
MMidAtlantic Retina
Phase 2
ATR-258
AAtrogi AB
Phase 2
Pharmacokinetics
PfizerPhase 1
Clenbuterol
UUniversity of Copenhagen
Preclinical
Triptorelin Acetate
IpsenPreclinical
Recombinant Hcg
UUniversitair Ziekenhuis Brussel
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Intravitreal Injections1 trial
Chlorhexidine1 trial
Vaginal Preparation With Chlorhexidine-alcohol vs. Povidine-iodine vs. Saline
Completed·—·Phase 2/3·NCT03640507·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Povidine-iodine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMidAtlantic Retina